BioCentury | Oct 26, 2018
Company News

Alexion moves into RNAi with Dicerna deal

...year to refocus on its core complement inhibitor franchise plus marketed enzyme replacement therapies Strensiq asfotase alfa...
...Hematology Mary Romeo Kanuma, sebelipase alfa (sbc-102, rhLAL) Onpattro, patisiran (ALN-TTR02, GENZ438027, GZ438027, SAR438027) ravulizumab (ALXN1210) Soliris, eculizumab (5G1.1) Strensiq, asfotase alfa (ENB-0040) Alexion...
BioCentury | Oct 24, 2018
Company News

Alexion moves into RNAi with Dicerna deal

...year to refocus on its core complement inhibitor franchise plus marketed enzyme replacement therapies Strensiq asfotase alfa...
...Consensus figures provided by FactSet. Mary Romeo Kanuma, sebelipase alfa (sbc-102, rhLAL) ravulizumab (ALXN1210) Soliris, eculizumab (5G1.1) Strensiq, asfotase alfa (ENB-0040) Alexion...
BioCentury | Sep 14, 2018
Regulation

Closing NICE’s Orphan gap

...in August 2017 for Strensiq asfotase alfa to treat pediatric-onset hypophosphatasia. Like Translarna, the evaluation of Strensiq...
...agreement established a national committee of clinical experts to determine starting and stopping criteria for Strensiq...
...also includes the collection of data from every patient in England and Wales who receives Strensiq...
BioCentury | Aug 31, 2018
Clinical News

Priority Review for Alexion's long-acting PNH therapy

...upon approval of Kanuma sebelipase alfa to treat lysosomal acid lipase deficiency (LAL-D) and Strensiq asfotase alfa...
BioCentury | Aug 20, 2018
Company News

Priority Review for Alexion's long-acting PNH therapy

...upon approval of Kanuma sebelipase alfa to treat lysosomal acid lipase deficiency (LAL-D) and Strensiq asfotase alfa...
BioCentury | Jun 22, 2018
Clinical News

Alexion submits BLA for long-acting C5 inhibitor for PNH

...FDA approved the company's Strensiq asfotase alfa to treat perinatal, infantile and juvenile-onset hypophosphatasia (HPP) (see “Asfotase Alfa...
BioCentury | Apr 20, 2018
Finance

Refilling Alexion’s cupboard

...which includes Soliris and its long-acting cousin ALXN1210 -- plus marketed enzyme replacement therapies Strensiq asfotase alfa...
...monophosphate (cPMP) replacement therapy (ALXN1101) Decuprate, bis-choline tetrathiomolybdate (WTX101, atn-224) Kanuma, sebelipase alfa (sbc-102, rhLAL) RhNAGLU (SBC-103) Strensiq, asfotase alfa (ENB-0040) Subcutaneous...
BioCentury | Sep 15, 2017
Company News

Alexion announces makeover plans

...in Phase III testing for PNH and aHUS, as well as enzyme replacement therapies Strensiq asfotase alfa...
...$1.4 billion in cash. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), New Haven, Conn. Business: Hematology, Endocrine/Metabolic, Autoimmune Mary Romeo ALXN1210 Kanuma Soliris Strensiq Alexion...
BioCentury | Sep 12, 2017
Company News

Alexion announces makeover plans

...in Phase III testing for PNH and aHUS, as well as enzyme replacement therapies Strensiq asfotase alfa...
...30, the company had $1.4 billion in cash. Alexion gained $1.14 to $144.07 on Tuesday. Mary Romeo ALXN1210 Kanuma Soliris Strensiq Alexion...
BioCentury | Jul 28, 2017
Company News

Alexion announces pipeline restructuring

...syndrome (aHUS). Enzyme replacement therapies Strensiq asfotase alfa and Kanuma sebelipase alfa remain in the fold. Strensiq...
Items per page:
1 - 10 of 94